AVAILABLE NOW!
2024 21st Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production
The 2024 21st Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most comprehensive, longest-running study of bioprocessing professionals. We highlight industry trends, insights, and opportunities.
FREE! 2024 – Top 10 Trends in Bioprocessing provides key trends identified in this year’s 21st Annual Report and Survey.
- 220 Biopharma companies surveyed
- 179 industry vendors and direct suppliers of materials
- 23 Countries represented
- ~500 Pages
- 12 Chapters
- 200+ Graphs and 20+ Tables
- Subject Matter Experts providing analysis
- Independent Sponsoring Organizations
| Digital Single-Office License | Digital Global Office License |
| Click here to Order | Contact us for Details |
Published by BioPlan Associates, Inc.,
April 2024,
978-1-934106-50-1
Highlights
NEW! This year’s edition provides additional Subject Matter Experts providing analysis on trends and future growth, and key takeaways in each chapter! This report’s 505 pages of data-rich analysis will help improve your decision making in biomanufacturing operations, with an in-depth analysis of capacity, production trends, benchmarks, and much more.
Coverage – Compare 220 Biomanufacturers vs CMOs; U.S. vs. European & Global Biomanufacturing
- Comprehensive overview of biopharmaceutical manufacturing industry trends, technologies, and challenges
- Industry budget trends and impact of the current economic environment
- Downstream purification problems and issues
- Current and projected biopharmaceutical industry bottlenecks
- Capacity utilization and current production levels
- Capacity bottlenecks – what’s being done to resolve
- Biopharm production trends and Outsourcing trends
- International offshoring through 2029
- Range of titers, growth
- Disposables: Spending growth; downstream uses; L&E’s; reasons for increasing/ restricting; budget increases; vendor satisfaction
- Batch failure rates & trends
- Selecting a CMO — Problems & solutions
- Quality management & PAT implementation
- Hiring and employment growth
- Supplier growth rates, and much more
Click here for the Table of Contents
- Overview
- Methodology
- CHAPTER 0: Demographics
- CHAPTER 1: Introduction and Discussion
- CHAPTER 2: Overview of Critical Issues in Bioprocessing
- CHAPTER 3: Emerging Issues in Biopharmaceutical Manufacturing
- CHAPTER 4: Capacity Utilization
- CHAPTER 5: Current and Future Capacity Constraints
- CHAPTER 6: Future Capacity Expansions
- CHAPTER 7: Outsourcing Trends in Biopharmaceutical Manufacturing
- CHAPTER 8: Disposables and Single-Use Systems in Biopharmaceutical Manufacturing
- CHAPTER 9: Downstream Purification
- CHAPTER 10: Hiring, Employment Growth and Training in Biopharmaceutical Manufacturing
- CHAPTER 11: New Methods: Continuous and Process Intensification, Cell and Gene Therapies
- CHAPTER 12: Suppliers to Biopharmaceutical Manufacturing and Life Sciences
SPECIAL! – Click here to listen to a recent podcast between Dodi Axelson, Discovery Matters Podcast and Eric Langer, Managing Partner of BioPlan Associates about BioPlan’s Annual Report on Biopharmaceutical Manufacturing Capacity and Production!
TESTIMONIALS for Annual Report – Click here for PDF
“It is always a pleasure and honor to contribute to such an important report, capturing the state of the industry.” – Stefan Schmidt, CEO, Evitria AG
“If you really want to get under the skin of the industry, this [BioPlan report] is where you go…Everything you need to know about the biopharma industry is in the BioPlan Annual Report…is the Granddaddy of reports…many pages if you want to get under the skin of the industry, this is where you go.” – Dodi Axelson, Discovery Matters Podcast, Dec 2021
“Your report has delivered significant value to us. We use it as a fundamental part of the research for our strategic planning. This report has helped us see market shifts, such as the predicted increase in needs for biotech-focused CMO’s that we used to position our company to better serve our clients. We consider this a must-have report to keep our business focused in the right direction.” – Jeff Hargroves, President, ProPharma Group
“BioPlan Associates Annual Reports are a valuable independent resource for monitoring drug manufacturing activities, trends and future needs.”- Jerold Martin, Former Pall Life Sciences
“The BioPlan Annual Report and Survey is and has always been a must-read, as it is the most comprehensive survey and results analysis to determine trends, requirements, and new demand of the biopharmaceutical industry. The report’s data and interpretation of the survey results are an invaluable tool for biomanufacturers and suppliers alike, as it thoroughly highlights the current status and future necessities. It not only is a snapshot report but a multi-year evaluation.” – Maik Jornitz, President, G-Con, LLC
“I have found each BioPlan Associates’ Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production to be particularly useful in my work. As managing editor for BioProcessing Journal, I refer to my print copies of the biomanufacturing survey reports regularly when recruiting and editing manuscripts. They are valuable components of my journal production ‘toolkit.'”- Marci J. Brown, Managing Editor, BioProcessing Journal
